Phase II trial of Lenvatinib in patients with metastatic or recurrent thymic carcinoma;REMORA trial
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Lenvatinib (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
- Acronyms REMORA trial
- 20 Jun 2017 Status changed from recruiting to suspended.
- 13 Apr 2017 Status changed from not yet recruiting to recruiting.
- 31 Mar 2017 New trial record